$HMMJ.TO

Decibel Cannabis Swings To Q1 Adjusted Profit As Revenue Jumps

Decibel Cannabis Company (DB.V) Thursday reported a swing to a first-quarter adjusted profit, as revenue increased.Adjusted earnings, which excludes most one-time items, was $3.07 million, or $0.01 per share, compared with an adjusted loss of $0.15 million, or nil per share, for the prior year period. The result was better than the consensus analyst estimate of nil per share, as polled by FactSet.Net revenue jumped 41% to $29.84 million, a tad above the $29.8 million expected. Growth was driven by continued international demand and success with recent domestic sales launches, the company said.For its fiscal second-quarter, Decibel is guiding to net revenue of $33 million to $35 million, implying year-over-year growth of 14% to midpoint of range.It maintained its 2026 full year net revenue guidance of $130 million to $135 million.Decibel shares were last seen unchanged at $0.13 on the TSX Venture Exchange.

Canopy Growth Adds "No Impact on Core Operating Performance"

Canopy Growth Says During YE Financial Reporting Process For Fiscal Year Ended March 31, 2026, the Co Identified a Technical Non-cash Accounting Error

Canopy Growth Also Plans to File Restated Financials for Fiscal Years Ended March 31, 2025 and March 31, 2024 and Certain Interim Periods

Canopy Growth Expects to Release Financial Results for Quarter and Fiscal Year Ended March 31, 2026, Before Markets Open on June 15, 2026

High Tide to Open New Canna Cabana in Toronto, Ontario

High Tide's (HITI.V) Canna Cabana retail cannabis store located at 150 Silver Reign Drive in Toronto, Ontario, is expected to begin selling recreational cannabis products and consumption accessories for adult use on May 17, 2026, the company said on Friday.This opening brings the company's total store count to 222 Canna Cabana locations across Canada and 98 in the province of Ontario, added the company."This new Rexdale location further strengthens our presence in the Greater Toronto Area and expands Canna Cabana into a high-density retail corridor with attractive long-term demand characteristics," said Raj Grover, founder and chief executive officer of High Tide. "We believe our differentiated discount-club model continues to resonate with consumers seeking value, convenience, and a broader loyalty-driven retail experience."The company's shares were last seen up $0.01 at $3.28 on the TSX Venture Exchange.Price: $3.28, Change: $+0.01, Percent Change: +0.31%

Auxly Cannabis Q1 Net Income Falls, Despite Higher Revs

Auxly Cannabis Group (XLY.TO) had lower net income in the first quarter compared to a year earlier, when a deferred tax recovery was included, but revenue was up, the company said Thursday.For the three months ended March 31, 2026, the company reported net income of near $3.5 million or breakeven per basic and diluted share, compared with $12.1 million or EPS of $0.01, a year earlier.The company noted Q1 2025 included $8.1 million of deferred tax recovery related to the change in estimated useful life of intangible assets. Excluding the deferred tax recovery, net income decreased by $0.5 million primarily driven by higher fair value loss on biological transformation and inventory. Excluding the impact of fair value adjustments on biological transformation and inventory and the deferred tax recovery in 2025, net income increased $5.8 million primarily due to improved gross profits and the reduction in interest and accretion expenses, partially offset by higher SG&A.Total net revenue increased to near $39.8 million in Q1, compared with $32.7 million, a year-ago. The growth was primarily driven by higher incremental volumes across the core portfolio, improved pricing across the flower portfolio, partially offset by price compression on vape products, it said.Also, it had Adjusted EBITDA of $12.3 million, an increase of 65% and representing 31% of net revenue, and cash flow from operations before working capital changes of $11.3 million, an increase of 102%, representing 92% conversion from Adjusted EBITDA. It also cited gross margin on cannabis inventory sold of 55% and an Adjusted EBITDA margin of 31%."Our top line success can be attributed to the value proposition offered by Back Forty, contributions from new innovations like South Point and All-in-One Boosted Vapes and improved distribution," said Auxly Chief Executive Hugo Alves.Auxly expects to allocate between $10 million to $12 million of cash flow from operations towards capital projects at Auxly Leamington in 2026.Shares of the company were last seen unchanged at $0.14 on the Toronto Stock Exchange.

Avicanna Swings to Net Comprehensive Loss in Q1

Avicanna (AVCN.TO) swung to a net comprehensive loss in the first quarter compared to a year-ago gain, it said on Thursday.For the three months ended March 31, 2026, the company reported net comprehensive loss of $214,653 or breakeven per share, compared with net comprehensive gain of $876,331 or net comprehensive gain per share of $0.01, a year earlier.Revenue for the first quarter increased to $6.7 million, compared with $6.3 million, a year-ago. Growth was primarily driven by an 11% increase in MyMedi.ca revenue and a 24% increase in product sales in Canada compared to the same period in 2025, it said.Shares of the company closed down 3.9% to $0.125 on Wednesday on the Toronto Stock Exchange.

Aurora Cannabis Says This Certification Gives It Exclusive Rights to "Grow, Propagate, and Sell Finished Products Produced From These Varieties"

Aurora Cannabis Granted Plant Breeders' Rights in Canada for Two Proprietary Cannabis Cultivars

Trulieve Announcing Proposed Domestication from British Columbia to Delaware

Organigram Global Swings to Q2 Net Loss, Net Revenue Falls; Updates Fiscal 2026 Guidance

Organigram Global (OGI.TO) swung to net loss in the second quarter as net revenue fell in the quarter, and updated its fiscal 2026 guidance, the company said on Tuesday.Second quarter net loss was C$0.9 million compared to net income of $42.5 million in Q2 Fiscal 2025. The decrease in net income in the current period was primarily attributable to lower fair value gains on derivative liabilities and preferred shares, as well as lower net revenue and gross margins compared to the prior year period, said the company. It added that the current period results were negatively impacted by a $5.8 million impairment loss related to the company's hemp-derived products business in the U.S.Second quarter net revenue decreased 9% to $59.8 million, from $65.6 million in the second quarter ended March 31, 2025, primarily driven by lower vape and infused pre-roll sales, said the company. The consensus estimates compiled by FactSet for Sales was $70.3 million."Q2 reflected our underperformance in vapes and temporary challenges in infused pre-roll production, compounded by slower industry growth," said James Yamanaka, Chief Executive Officer of Organigram. "We acted quickly to address these issues, and the operational changes and product enhancements we have implemented are already beginning to stabilize performance. Combined with continued improvements in yields and flower potency, and the contribution from Sanity Group beginning in Q3, we believe the business is positioned for stronger execution and improved performance in the second half of fiscal 2026."As of March 31, 2026, the company had total cash, including restricted cash and short-term investments, of $54.8 million. Subsequent to quarter end, it deployed the majority of its total cash position in consideration of the Sanity Group acquisition and secured $60 million in debt financing from ATB Financial of which $20 million was allocated to the Sanity Group acquisition, the company added.The company is now projecting net revenue to exceed $350 million in fiscal 2026, with adjusted EBITDA and adjusted gross margin exceeding fiscal 2025 performance, free cash flow approximately break even, and capital expenditures of less than $10 million."Following the acquisition of Sanity Group, which closed in April 2026, the company is updating its Fiscal 2026 guidance. Prior to the acquisition, shipments to Sanity Group were recognized as revenue upon shipment to Sanity Group; post-acquisition, shipments to Sanity Group are recognized as revenue upon ultimate sale by Sanity Group to third parties."The company originally issued its fiscal 2026 guidance in Q4 Fiscal 2025, prior to the acquisition of Sanity Group, which closed in April 2026, and had contemplated net revenue exceeding $300 million, higher adjusted gross margin and adjusted EBITDA relative to fiscal 2025, positive free cash flow, and capital expenditures of less than $10 million.

Organigram Q2 Adjusted EBITDA $0.9M, Down 82% YoY

Organigram Q2 Net Revenue $59.8M, Down 9% YoY

Cronos Up More Than 8% As Q1 Net Income More Than Doubles, Beats Forecasts

Cronos (CRON.TO), up near 9% on last look, said Monday that first quarter net income more than doubled, beating estimates, boosted by higher revenues.Net income attributable to shareholders more than doubled to US$13.75 million or $0.04 per diluted share, from $6.12 million or US$0.02 per share in the prior year period. The result beat the consensus analyst estimate of $0.01 per share, according to FactSet.Net revenue jumped 40% to US$45.2 million over the same period. The increase was mainly due to higher cannabis flower sales in Israel and other countries, which carry no excise taxes, and higher cannabis extract and flower sales in the Canadian market, the company said.Among other highlights, it said net income of $15.7 million in Q1 2026 increased by $8.0 million from Q1 2025. The increase was primarily due to higher gross profit and other income, partially offset by higher operating expenses.Adjusted EBITDA of $5.1 million in Q1 2026 improved by $2.8 million from Q1 2025. The improvement was primarily driven by higher gross profit, partially offset by higher operating expenses due to higher sales and marketing, general and administrative, and research and development costs.It cited a balance sheet with $822 million in total cash and cash equivalents.Cronos shares were last seen $0.44, to $3.91, on the Toronto Stock Exchange.Price: $3.79, Change: $+0.32, Percent Change: +9.22%

High Tide Announces Purchases of Shares by Insiders

High Tide (HITI.V) said on Monday that certain officers, directors, and consultants, led by the company's president and chief executive officer, acquired 90,882 common shares in the capital of High Tide on the open market between May 6, 2026, and May 8, 2026, at an average price of $3.39 per common share.With these purchases, insiders and certain consultants, in the aggregate, now own or control around 7.72 million common shares, representing approximately 8.8% of the company's issued and outstanding common shares as of today, it said on Monday."We believe the operational momentum across our retail platform, international business, and balance sheet continues to strengthen, and these insider purchases reflect our confidence in the long-term value we are building," said Raj Grover, Founder and Chief Executive Officer of High Tide.

LEEF Brands Files Applications for DEA Registration

LEEF Brands (LEEF.CN) has filed applications for registration with the U.S. Drug Enforcement Administration (DEA) following recent federal cannabis rescheduling developments, the company said on Friday.The applications are a "key step" in positioning LEEF to participate in potential interstate commerce and international export channels as regulatory frameworks evolve, the company stated."Rescheduling is the most significant change our industry has seen in over 50 years," said Micah Anderson, Chief Executive Officer of LEEF Brands. "We've spent years building a low-cost, vertically integrated platform designed for this moment. For the first time in this industry's history, federal policy is moving in a direction that makes what we do more valuable, not less."Shares of the company were last seen up $0.0025 at $0.2275 on the Canadian Securities Exchange.Price: $0.23, Change: $+0.01, Percent Change: +2.22%

Canopy Growth and Spectrum Therapeutics Expanding Medical Portfolio With New 30 And 90-Pack Softgels and Enhanced Dosing Options

High Tide Reports Q2 Preliminary Tonnage Data From its 51%-owned German Subsidiary, Remexian Pharma GmbH

High Tide (HITI.V, HITI) reported preliminary tonnage data from its 51%-owned German subsidiary, Remexian Pharma GmbH, for the second fiscal quarter ended April 30, 2026, on Wednesday.Remexian sold 7.6 tonnes of medical cannabis into the German market during the quarter, representing the "highest quarterly distribution volume in its history," stated the company.Volumes increased 21% on a sequential basis and 49% year over year, it added."Distributing 7.6 tonnes in a single quarter is not just a record for Remexian - it is clear evidence that our model is scaling in the largest medical cannabis market in Europe," said Raj Grover, Founder and Chief Executive Officer of High Tide."This level of sequential and year-over-year growth reinforces our conviction that Germany is only the beginning. We are building a repeatable, capital-efficient distribution engine that can be expanded across Europe, subject to regulatory conditions. We fully intend to leverage this momentum to continue taking share in Germany while methodically entering additional high-growth markets," added Grover.

Curaleaf Swings to Q1 Profit As Revenues Beat Expectations

Curaleaf (CURA.TO) reported a swing to a surprise first-quarter profit, boosted by better than expected revenues.The company reported net income from continuing operations of US$70.1 million, or US$0.09 per share, compared with a loss of US$50.1 million, or a loss of US$0.09 per share. Analysts polled by FactSet had forecast a loss of US$0.08 per share.Revenue climbed 6% over the same period, to US$324 million, beating the US$317 million forecast."The macro headwinds that constrained growth over the past three years are now beginning to turn into meaningful tailwinds. Moreover, the historic rescheduling of medical cannabis provides a shift in the trajectory of our business and the industry overall, for which we are well-positioned," said chief executive Boris Jordan. "The investments we've made in the core pillars of our "Built for Growth" strategy are translating directly into tangible performance," he added.Curaleaf shares closed up $0.28, to $4.73 on Tuesday on the Toronto Stock Exchange.